Search

Search Results

• NATION-WIDE SURVEY ON THE USE OF THROMBOPOIETIN RECEPTOR AGONISTS (TPO-RA) FOR THE MANAGEMENT OF IMMUNE THROMBOCYTOPENIA IN CURRENT CLINICAL PRACTICE IN ITALY

  Francesco Rodeghiero, Dr. Mariasanta Napolitano, Nicola Vianelli, Lisanna Ghiotto, Silvia Cantoni, Giuseppe Carli, Monica Carpenedo, Valentina Carrai, Ugo Consoli, Gaetano Giuffrida, Elisa Lucchini, Elena Rossi, Cristina Santoro

  e2023019

  2023-02-28

  https://doi.org/10.4084/MJHID.2023.019

  2468

  PDF: 1290

  PDF Appendix: 756

  HTML: 516

• USE OF HEMATOPOIETIC GROWTH FACTOR IN THE MANAGEMENT OF HEMATOLOGICAL SIDE EFFECTS ASSOCIATED TO ANTIVIRAL TREATMENT FOR HCV HEPATITIS

  Paola Mancino, Katia Falasca, Claudio Ucciferri, Eligio Pizzigallo, Jacopo Vecchiet

  e2010003

  2010-03-26

  https://doi.org/10.4084/mjhid.2010.003

  1178

  PDF: 553

  HTML: 957

• TYROSINE KINASE INHIBITORS AND INTERFERON

  Maria Dimou, Panagiotis Panagiotidis

  e2014006

  2014-01-02

  https://doi.org/10.4084/mjhid.2014.006

  2947

  PDF: 1472

  HTML: 3097

  Cover Letter: 233

• Sorafenib induced Hand Foot Skin Rash in FLT3 ITD mutated Acute Myeloid leukemia- A case report and review of literature

  Jayastu Senapati, Anup J Devasia, Abhijeet Ganapule, Leni George, Auro Viswabandya

  e2014016

  2014-02-17

  https://doi.org/10.4084/mjhid.2014.016

  2092

  PDF: 974

  HTML: 1774

  Sorafenib induced Hand Foot Skin Rash in FLT3 ITD mutated AML- IMAGES: 189

• A case of Pseudo-Richter Transformation following zanubrutinib discontinuation in CLL

  Luca Laurenti, Tommaso Quaranta, Annamaria Tomasso, Luca Stirparo, Pier Luigi Abbate, Arianna Bakacs, Natalia Cappoli, Arianna Di Napoli, Dimitar Efremov, Flaminia Bellisario, Valter Gattei, Carmelo Caldarella, Maria Luisa Calcagni, Francesco Autore, Idanna Innocenti

  e2026070

  2026-09-01

  https://doi.org/10.4084/MJHID.2026.070

  53

  PDF: 32

  Html: 5

• IMATINIB IN CHRONIC MYELOID LEUKEMIA: AN OVERVIEW

  Tomasz Sacha

  e2014007

  2013-12-31

  https://doi.org/10.4084/mjhid.2014.007

  4950

  PDF: 2922

  HTML: 2343

• Severe acute axonal neuropathy following treatment with arsenic trioxide for acute promyelocytic leukemia: a case report

  Marcus Kuhn, Mithia Nabergoj, Kety Sammartin, Fabrizio Vianello

  e2016023

  2016-05-01

  https://doi.org/10.4084/mjhid.2016.023

  4161

  PDF: 1045

  HTML: 1628

• Successful planned pregnancy through vitrified-warmed embryo transfer in a woman with chronic myeloid leukemia: case report and literature review

  Toshifumi Takahashi

  e2020005

  2020-01-01

  https://doi.org/10.4084/mjhid.2020.005

  1891

  PDF: 1292

  HTML: 364

• Azacytidine failure revisited: an appraisal based on real life data from the MDS registry of the Hellenic Myelodysplastic Syndrome Study Group (HMDS). Azacytidine failure revisited

  IOANNIS KOTSIANIDIS

  e2019045

  2019-06-25

  https://doi.org/10.4084/mjhid.2019.045

  1152

  PDF: 913

  HTML: 291

• BCR SIGNALING INHIBITORS: AN OVERVIEW OF TOXICITIES ASSOCIATED WITH IBRUTINIB AND IDELALISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

  Lorenzo Falchi, Jessica M Baron, Carrie Anne Orlikowski, Alessandra Ferrajoli

  e2016011

  2016-02-10

  https://doi.org/10.4084/mjhid.2016.011

  4421

  PDF: 1528

  HTML: 3725

• TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS WITH MIDOSTAURIN: PRACTICAL GUIDANCE FOR OPTIMAL THERAPY AND MANAGEMENT Advanced systemic mastocytosis and midostaurin

  Cristina Papayannidis, Vincenzo Federico, Luana Fianchi, Patrizia Pregno, Novella Pugliese, Alessandra Romano, Federica Irene Grifoni

  e2022073

  2022-10-29

  https://doi.org/10.4084/MJHID.2022.073

  1356

  PDF: 1083

  HTML: 425

• GILTERITINIB (XOSPATA ®) IN TURKEY: EARLY ACCESS PROGRAM RESULTS Gilteritinib (XOSPATA ®) in Turkey

  Mehmet Hilmi DOGU, Ali Irfan Emre TEKGUNDUZ, Burak DEVECI, Gulten KORKMAZ, Melda COMERT, Omur Gokmen SEVINDIK, Osman YOKUS, Istemi SERIN

  e2023031

  2023-04-28

  https://doi.org/10.4084/MJHID.2023.031

  1527

  PDF: 948

  Suppl. Files: 470

  HTML: 295

• IRON CHELATION THERAPY WITH DEFERASIROX IN THE MANAGEMENT OF IRON OVERLOAD IN PRIMARY MYELOFIBROSIS

  Elena Maria Elli, Angelo Belotti, Andrea Aroldi, Matteo Parma, Pietro Pioltelli, Enrico Maria Pogliani

  e2014042

  2014-05-30

  https://doi.org/10.4084/mjhid.2014.042

  2212

  PDF: 1192

  HTML: 2016

• Hypophosphatemic osteomalacia associated with tenofovir: a multidisciplinary approach is required.

  Giuseppe Vittorio De Socio, Gianluigi Fabbriciani, Marco Massarotti, Salvatore Messina, Enisia Cecchini, Bianca Marasini

  e2012025

  2012-05-04

  https://doi.org/10.4084/mjhid.2012.025

  1450

  PDF: 899

  HTML: 10093

  cover letter to the editor: 188

  tile page: 271

• REVIEW AND RECOMMENDATIONS ON MANAGEMENT OF ADULT FEMALE THALASSEMIA PATIE?TS WITH HYPOGONADISM BASED ON LITERATURE REVIEW AND EXPERIENCE OF ICET-A NETWORK SPECIALISTS

  Vincenzo De Sanctis

  e2017001

  2017-01-01

  https://doi.org/10.4084/mjhid.2017.001

  6229

  PDF: 1471

  HTML: 2032

• PROGNOSTIC SIGNIFICANCE OF TRANSCRIPT-TYPE BCR/ABL1 IN CHRONIC MYELOID LEUKEMIA

  matteo molica, elisabetta abruzzese, massimo breccia

  e2020062

  2020-09-12

  https://doi.org/10.4084/mjhid.2020.062

  4113

  PDF: 1668

  HTML: 813

• DIAGNOSTIC ACCURACY OF CLINICAL TOOL ‘STOPS’ AND SERUM PROCALCITONIN FOR OPTIMIZING ANTIBIOTIC THERAPY IN NEONATAL SEPSIS STOPS and procalcitonin for optimizing antibiotics in neonatal sepsis

  Vishal Vishnu Tewari

  e2021019

  2021-02-26

  https://doi.org/10.4084/mjhid.2021.019

  1835

  PDF: 634

  HTML: 468

• Successful management of pregnancy and hepatic toxicity in a CML female patient treated with nilotinib : a case report and a review

  Domenico Santorsola, Elisabetta Abruzzese

  e2015020

  2015-02-12

  https://doi.org/10.4084/mjhid.2015.020

  2109

  PDF: 1254

  HTML: 1661

• HOW I TREAT FEBRILE NEUTROPENIA

  Marcio Nucci

  e2021025

  2021-02-26

  https://doi.org/10.4084/mjhid.2021.025

  7116

  PDF: 4053

  HTML: 664

• DIFFERENTIATION SYNDROME IN PROMYELOCYTIC LEUKEMIA : CLINICAL PRESENTATION, PATHOGENESIS AND TREATMENT

  Eduardo Magalhães Rego, Gil Cunha de Santis

  e2011048

  2011-10-24

  https://doi.org/10.4084/mjhid.2011.048

  3390

  PDF: 1445

  HTML: 3408

• IMMUNE THROMBOTIC THROMBOCYTOPENIC PURPURA: PATHOPHYSIOLOGY, DIAGNOSIS AND OPEN ISSUES

  Silvia Maria Trisolini, Alessandro Laganà, Saveria Capria

  e2024060

  2024-06-29

  https://doi.org/10.4084/MJHID.2024.060

  2506

  PDF: 1936

  HTML: 173

• LETERMOVIR PRIMARY CYTOMEGALOVIRUS PROPHYLAXIS IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS: COULD INFECTION AND DISEASE NO LONGER BE A SIGNIFICANT PROBLEM? Letermovir and Cytomegalovirus Prophylaxis in HSCT

  Fabian Herrera

  e2024039

  2024-04-30

  https://doi.org/10.4084/MJHID.2024.039

  1593

  PDF: 1066

  HTML: 139

• COMPARISON OF THREE DISTINCT PROPHYLACTIC AGENTS AGAINST INVASIVE FUNGAL INFECTIONS IN PATIENTS UNDERGOING HAPLO-IDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION AND POST-TRANSPLANT CYCLOPHOSPHAMIDE

  Jean Elcheikh

  e2015048

  2015-08-21

  https://doi.org/10.4084/mjhid.2015.048

  1967

  PDF: 1052

  HTML: 1387

• Guest Editor: Pellegrino Musto HOW FIRST-LINE THERAPY IS CHANGING IN NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS.

  Daniele Derudas

  e2025025

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.025

  1687

  PDF: 1431

  HTML: 166

• COMPARISON OF EMPIRIC ANTIBIOTIC ESCALATION THERAPY WITH VANCOMYCIN (VAN) VERSUS LINEZOLID (LIN) IN PATIENTS WITH FEBRILE NEUTROPENIA

  Karin Mayer, Nicolaus Hegge, Ernst Molitor, Peter Brossart, Corinna Hahn-Ast

  e2022032

  2022-04-28

  https://doi.org/10.4084/MJHID.2022.032

  1154

  PDF: 587

  HTML: 261

• EFFICACY AND SAFETY OF THALIDOMIDE IN PATIENTS WITH TRANSFUSION-DEPENDENT β-THALASSEMIA: A SYSTEMATIC REVIEW, META-ANALYSIS AND GRADE EVALUATION

  Jialian Li, Ping Ji, Qinyue Zhong, Lin Dong, Hai Yi, Baiyu Chen, Xu Zhang, Tingting Duan

  e2026033

  2026-04-30

  https://doi.org/10.4084/MJHID.2026.033

  338

  PDF: 358

  Suppl. Files: 56

  HTML: 91

• Guest Editor: Pellegrino Musto AN UPDATE OF THE APPROPRIATE SEQUENCING FOR SALVAGE THERAPIES IN MULTIPLE MYELOMA

  Gregorio Barila', Francesca Rezzonico, Laura Pavan, Alessandro Corso, Renato Zambello

  e2025043

  2025-04-30

  https://doi.org/10.4084/MJHID.2025.043

  1251

  PDF: 998

  HTML: 265

• Challenging management of severe differentiation syndrome in pediatric acute promyelocytic leukemia treated with ATRA/ATO

  Alessandro Molinaro, Daniela Zanta, Maria Luisa Moleti, Fiorina Giona, Valentino Conter, Carmelo Rizzari, Andrea Biondi, Anna Maria Testi

  e2022027

  2022-02-27

  https://doi.org/10.4084/MJHID.2022.027

  2290

  HTML: 278

  PDF: 662

• TYROSINE KINASE INHIBITORS AND PREGNANCY

  Elisabetta Abruzzese, Malgorzata Monika Trawinska, Paolo De Fabritiis, Alessio Pio Perrotti

  e2014028

  2014-04-07

  https://doi.org/10.4084/mjhid.2014.028

  3740

  PDF: 1720

  HTML: 2692

• CLASSICAL HODGKIN LYMPHOMA TODAY

  Francesco D'Alò, Gabriele Schiaffini, Daniele Mazzoni, Eleonora Alma, Flaminia Bellisario, Marcello Viscovo, Elena Maiolo, Silvia Bellesi, Stefan Hohaus

  2026-06-30

  https://doi.org/10.4084/MJHID.2026.055

  806

  PDF: 486

  HTML: 189

• Guest Edtor: Pellegrino Musto NOVELTIES ON MULTIPLE MYELOMA FROM THE MAIN 2024 HEMATOLOGY CONFERENCES

  Sonia Morè, Laura Corvatta, Valentina Maria Manieri, Erika Morsia, Antonella Poloni, Massimo Offidani

  e2025027

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.027

  1526

  PDF: 1306

  HTML: 385

• BRUTON’S TYROSINE KINASE (BTK) MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A CLINICAL VIEW.

  Stefano Molica

  e2025053

  2025-06-29

  https://doi.org/10.4084/MJHID.2025.053

  1790

  PDF: 1017

  HTML: 345

• THALIDOMIDE FOR PATIENTS WITH THALASSEMIA INTERMEDIA: A RETROSPECTIVE MULTICENTER CLINICAL STUDY

  Kun Yang, Yi Wu, Yali Zhou, Tianhong Zhou, Li Wang, Zhili Geng, Xiaolin Yin

  e2020021

  2020-04-27

  https://doi.org/10.4084/mjhid.2020.021

  2309

  PDF: 1287

  HTML: 407

• Impressive continuous complete response after mogamulizumab in a heavily pre-treated Sézary syndrome patient

  Pier Luigi Zinzani, Ginevra Lolli, Beatrice Casadei, Lisa Argnani, Laura Nanni, Michele Cavo

  e2020040

  2020-06-28

  https://doi.org/10.4084/mjhid.2020.040

  1175

  PDF: 713

  HTML: 220

• PATIENTS WITH HAEMOGLOBINOPATHIES AND CHRONIC HEPATITIS C: A REALLY DIFFICULT TO TREAT POPULATION IN 2016?

  Kalliopi Zachou, Pinelopi Arvaniti, Nikolaos K. Gatselis, Kalliopi Azariadis, Georgia Papadamou, Eirini Rigopoulou, George N. Dalekos

  e2017003

  2017-01-01

  https://doi.org/10.4084/mjhid.2017.003

  2994

  PDF: 1012

  HTML: 2118

  Cover letter: 198

• HOW THE HEMOSTASIS LABORATORY CAN HELP CLINICIANS TO MANAGE PATIENTS ON ORAL ANTICOAGULANTS

  Armando Tripodi

  e2024027

  2024-02-29

  https://doi.org/10.4084/MJHID.2024.027

  1070

  PDF: 1417

  HTML: 159

• Genomic integration of HHV-6 mimicking viral reactivation after autologous stem cell transplantation

  rossana mineri, Jacopo Mariotti, Barbara Sarina, Lucio Morabito, roberto crocchiolo, stefania bramanti, tiziana sarno, federica tordato, carmelo carlo-stella, armando santoro, Luca Castagna

  e2018013

  2018-02-15

  https://doi.org/10.4084/mjhid.2018.013

  3147

  PDF: 764

  HTML: 435

• Early use of thrombopoietin receptor agonists (Tpo-Ras) in clinical practice: results from an Italian survey on behalf of the GIMEMA Working Group Anemia and Thrombocytopenia

  Mariasanta Napolitano, elisa lucchini, maria rosaria de paolis, antonio urso, nicola vianelli, francesco zaja, cristina santoro

  e2025041

  2025-04-30

  https://doi.org/10.4084/MJHID.2025.041

  947

  PDF: 719

  HTML: 209

• JADENU® SUBSTITUTING EXJADE® IN IRON OVERLOADED ?- THALASSEMIA MAJOR (BTM) PATIENTS: A PRELIMINARY REPORT OF THE EFFECTS ON THE TOLERABILITY, SERUM FERRITIN LEVEL, LIVER IRON CONCENTRATION AND BIOCHEMICAL PROFILES

  Vincenzo De Sanctis

  e2018064

  2018-10-27

  https://doi.org/10.4084/mjhid.2018.064

  2742

  PDF: 1252

  HTML: 442

• CLINICAL USEFULNESS OF BROCHOALVEOLAR LAVAGE IN THE MANAGEMENT OF PULMONARY INFILTRATES IN ADULTS WITH HAEMATOLOGICAL MALIGNANCIES AND STEM CELL TRANSPLANTATION

  Laura Jorge, Diego Torres, Agustín Languasco, Pablo Rodriguez, Pablo Bonvehí, Elena Temporiti, Silvia Relloso, Cristina Videla, Fabián Herrera

  e2020025

  2020-05-01

  https://doi.org/10.4084/mjhid.2020.025

  9319

  PDF: 818

  HTML: 270

• Ponatinib induced improvement of cutaneous lesions associated to accelerated phase of Ph-positive chronic myeloid leukemia

  Massimo Breccia, Gioia Colafigli, Luisa Quattrocchi, elisabetta abruzzese, giuliana alimena

  e2016016

  2016-02-20

  https://doi.org/10.4084/mjhid.2016.016

  2963

  PDF: 719

  HTML: 1958

  figure 1: 195

  figure 2: 191

• ANTIFUNGAL THERAPY IN HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS

  Alessandro Busca, Livio Pagano

  e2016039

  2016-09-01

  https://doi.org/10.4084/mjhid.2016.039

  4855

  PDF: 1602

  HTML: 2263

  Untitled: 251

  Untitled: 264

  Untitled: 284

  Untitled: 235

  Untitled: 253

• COMPARISON OF THE POWER OF PROCALCITONIN AND C-REACTIVE PROTEIN TO DISCRIMINATE BETWEEN DIFFERENT AETIOLOGIES OF FEVER IN PROLONGED PROFOUND NEUTROPENIA: A SINGLE-CENTRE PROSPECTIVE OBSERVATIONAL STUDY.

  Anke Verlinden, Veronique De Vroey, Herman Goossens, Ella Roelant, Ann Van de Velde, Zwi Berneman, Wilfried Schroyens, Alain Gadisseur

  e2019023

  2019-02-26

  https://doi.org/10.4084/mjhid.2019.023

  6849

  PDF: 1119

  HTML: 507

• WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE

  Maddalena Mazzucchelli, Anna Maria Frustaci, Marina Deodato, Roberto Cairoli, Alessandra Tedeschi

  e2018004

  2018-01-01

  https://doi.org/10.4084/mjhid.2018.004

  7819

  PDF: 2481

  HTML: 2115

  Table 1.: 246

  Table 2.: 257

  Table 3.: 237

  Table 4.: 232

• EVOLVİNG PARADİGMS İN THE MANAGEMENT OF PRİMARY IMMUNE THROMBOCYTOPENİA İN ADULTS: FROM CORTİCOSTEROİDS TO TARGETED BİOLOGİC THERAPİES

  Massimo Martino, Laura Giordano, Maria Bruna Greve, Violetta Marafioti, Caterina Alati

  e2026067

  2026-09-01

  https://doi.org/10.4084/MJHID.2026.067

  50

  PDF: 51

  Html: 2

• PATHOBIOLOGY AND TREATMENT OF HEPATITIS VIRUS-RELATED THROMBOCYTOPENIA

  Roberto Stasi, Lian Wea Chia, Pallavi Kalkur, Robert Lown, Muriel S. Shannon

  e2009023

  https://doi.org/10.4084/mjhid.2009.023

  915

  PDF: 605

  HTML: 1469

• First-Line Flumatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: A 3-Month Landmark-Evaluable Real-World Experience

  Dangui Chen

  e2026066

  2026-09-01

  https://doi.org/10.4084/MJHID.2026.066

  46

  PDF: 24

  Html: 4

• SECONDARY PROPHYLAXIS OF VENOUS THROMBOEMBOLISM (VTE) WITH LOW DOSE APIXABAN OR RIVAROXABAN: RESULTS FROM A PATIENT POPULATION WITH MORE THAN 2 YEARS OF MEDIAN FOLLOW-UP

  Alessandro Laganà, Giovanni Manfredi Assanto, Chiara Masucci, Mauro Passucci, Livia Donzelli, Alessandra Serrao, Erminia Baldacci, Cristina Santoro, Antonio Chistolini

  e2024020

  2024-02-29

  https://doi.org/10.4084/MJHID.2024.020

  1174

  PDF: 1275

  HTML: 120

• DRUG THERAPY IN THE PROGRESSED CML PATIENT WITH MULTI-TKI FAILURE

  Ibrahim C. Haznedaroglu

  e2015014

  2015-12-02

  https://doi.org/10.4084/mjhid.2015.014

  277810

  PDF: 1849

  HTML: 3898

• Late-onset hepatic veno-occlusive disease after allografting: report of two cases with atypical clinical features successfully treated with defibrotide.

  Alessia Castellino, Stefano Guidi, Chiara Dellacasa, Antonella Gozzini, Irene Donnini, Chiara Nozzoli, Sara Manetta, Semra Aydin, Luisa Giaccone, Moreno Festuccia, Lucia Brunello, Enrico Maffini, Benedetto Bruno, Ezio David, Alessandro Busca

  e2018001

  2018-01-01

  https://doi.org/10.4084/mjhid.2018.001

  4306

  PDF: 1152

  HTML: 1032